Skip to main content
. Author manuscript; available in PMC: 2016 Mar 18.
Published in final edited form as: Leuk Lymphoma. 2015 Oct 12;57(3):635–643. doi: 10.3109/10428194.2015.1075019

Table IV.

Response Data

Best Response No. of patients
Complete response (CR) 0
Partial response (PR) 1a
Stable disease (SD) 2b
Progressive disease (PD) 17
Not Evaluable (NE) 0
a

DLBCL; prior autologous SCT

b

1 MCL and 1 DLBCL